Bryony is a PhD candidate jointly between the Department of Infectious Disease and the Centre for Health Economics, Policy, and Innovation (CHEPI) at Imperial College Business School.
Her research focuses on the evaluation of policies to improve access to essential medicines. She has focused largely on access to high-cost hepatitis C medicines in low- and middle-income countries. Her PhD is supervised by Prof Graham Cooke (Department of Infectious Disease) and Prof Marisa Miraldo (Imperial College Business School).
Bryony holds a Master’s of Public Health (Global Health) from Imperial College London and a Master’s in Natural Sciences from University College London. Bryony previously worked for the Clinton Health Access Initiative (Rwanda) and has provided statistical support for clinical studies.
et al., 2020, Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial, Lancet Hiv, Vol:7, ISSN:2352-3018, Pages:E666-E676
Simmons B, Cooke GS, Miraldo M, 2019, Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis, The Lancet Global Health, Vol:7, ISSN:2214-109X, Pages:e1189-e1196
et al., 2019, Dolutegravir plus two different prodrugs of tenofovir to treat HIV, New England Journal of Medicine, Vol:381, ISSN:0028-4793, Pages:803-815
et al., 2019, Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission, The Lancet Gastroenterology and Hepatology, Vol:4, ISSN:2468-1253, Pages:135-184
et al., 2017, Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda., BMC Infectious Diseases, Vol:17, ISSN:1471-2334
et al., 2016, Risk of late relapse or reinfection with Hepatitis C virus after achieving a sustained virological response: A systematic review and meta-analysis, Clinical Infectious Diseases, Vol:62, ISSN:1537-6591, Pages:683-694
et al., 2015, Long-term treatment outcomes of patients infected with Hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a Sustained Virological Response, Clinical Infectious Diseases, Vol:61, ISSN:1537-6591, Pages:730-740